Proactive Investors - Run By Investors For Investors

Amazon now carrying NovaBay Pharmaceuticals’ Avenova eye-care product; shares skyrocket

Avenova is available without a prescription on Amazon's new direct direct-to-consumer online channel
eye
The Avenova spray removes bacteria and debris on and around the eyelid that contribute to bacterial eye infections

Shares of NovaBay Pharmaceuticals Inc (NYSEAMERICAN:NBY) increased more than six-fold Monday after the company announced that its Avenova eye-care product is now available without a prescription at Amazon.com.

The Emeryville, California-based biopharmaceutical company said customers can purchase Avenova on Amazon.com Inc's (NASDAQ:AMZN) new direct direct-to-consumer online channel.

NovaBay’s stock exploded 541% to $2.04 a share on heavy volume Monday afternoon. 

Treating dry eyes

Avenova, a spray, is designed for the removal of bacteria and debris on and around the eyelid margin that contribute to bacterial eye infections, which represent approximately 85% of the dry eye market, the company said.

“While prescription Avenova continues to be available through retail pharmacies and direct in-office sales by certain eye-care specialists, patients and physicians have asked for greater accessibility to the product," said CEO Justin Hall. "In response, we are launching our new US direct-to-consumer channel, which is a significant step in ensuring easy access at an affordable price."

Avenova, or Avenova Direct as the online version is called, is available from Amazon in the US in a 20 milliliter size for $29.99, the company said.

-- updates stock price --- 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full NBY profile View Profile

NovaBay Pharmaceuticals Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
man with erectile dysfunction
April 26 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use